

Next Generation Immunotherapy Discoveries

Organizers: Innate Pharma, Mount Sinai School of Medicine
Mount Sinai School of Medicine, New York - October 3, 2024

MORNING PROGRAM

9:30 am – 10:00 am *Opening coffee*

10:00 am – 10:15 am **Welcome - Hervé Brailly**
Chairman of the Executive Board and Chief Executive Officer of Innate Pharma

Next generation immunotherapy discoveries applied to clinic

Chair: Joao Monteiro, Nature Medicine

10:15 am – 10:45 am Pierluigi Porcu, Thomas Jefferson University
"Novel therapies in T-cell malignancies: preclinical and clinical studies"

10:45 am – 11:15 am Eric Vivier, Innate Pharma; Centre d'Immunologie Marseille-Luminy
"Harnessing NK cells in therapies"

11:15 am – 11:30 am *Break*

11:30 am – 12:00 pm Lorenzo Falchi, Memorial Sloan Kettering Cancer Center
"NK engagers for the treatment of B-cell lymphoma: Preclinical development and clinical applications"

12:00 pm – 12:30 pm Katy Rezvani, MD Anderson Cancer Center
"NK cells: next generation cell therapies for cancer"

12:30 pm – 2:00 pm *Lunch Break*

AFTERNOON PROGRAM

Next generation immunotherapy discoveries

Chair: Amir Horowitz, Mount Sinai School of Medicine

2:00 pm – 2:30 pm Dimitri Skokos, Regeneron Pharmaceuticals, Inc.
"Tumor-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy "cold" tumors "hot""

2:30 pm – 3:00 pm Miriam Merad, Mount Sinai School of Medicine
"Targeting pathogenic myelopoiesis in cancer"

3:00 pm – 3:30 pm Antoni Ribas, University of California
"Effects of MHC class I expression in PD-1 blockade therapy"

3:30 pm – 4:00 pm *Break*

4:00 pm – 4:30 pm Tom Marron, Mount Sinai School of Medicine
"Therapeutic targeting of Type-2 immunity in cancer"

4:30 pm – 5:00 pm Diane Mathis, Harvard Medical School
"Tissue-Treg control of local IFN γ responses, a commonality"
